

Supplemental Figures for:
A Phase II Randomized Trial (G027827) of First-Line FOLFOX Plus Bevacizumab with or Without the MET Inhibitor Onartuzumab in Patients with Metastatic Colorectal Cancer
Johanna Bendell et al.

Figure S1. MET STEPPs for PFS. **(A):** 30 patients. **(B):** 40 patients.
Abbreviations: CI, confidence interval; HR, hazard ratio; MET, mesenchymal-epithelial transition; PFS, progression-free survival; STEPP, subpopulation treatment effect pattern plot.




Figure S2. HGF STEPPs. **(A):** PFS. **(B):** OS.

Abbreviations: CI, confidence interval; HGF, hepatocyte growth factor; OS, overall survival; PFS, progression-free survival; STEPP, subpopulation treatment effect pattern plot.






Figure S3. Exploratory subgroup analyses according to biomarker expression status. **(A):** PFS. **(B):** OS. Abbreviations: Bev, bevacizumab; CI, confidence interval; MET-Neg, mesenchymal-epithelial transition negative; MET-Pos, mesenchymal-epithelial transition positive; NE, not estimable; Ona, onartuzumab; OS, overall survival; Pbo, placebo; PFS, progression-free survival.

A



B

